SYNGENE Q4 FY24 earnings call.
A source-linked concall view: reported numbers, management language, guidance, commitments and risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹916.9 Cr
verified against source
Revenue YoY
9%
reported change
EBITDA
Pending
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Syngene reported a challenging Q4 FY24 with revenue from operations declining 8% YoY, marking the trough of a tough year for pharma research services amid US biotech funding headwinds. However, full-year FY24 performance showed resilience with 9% revenue growth to INR 3,489 crore and 12% PAT growth to INR 519 crore. The Q4 EBITDA margin expanded 300bps YoY to 35%, driven by material cost efficiencies and lower power costs. Management guided for high single-digit to low double-digit constant currency revenue growth for FY25, expecting a back-loaded recovery with H1 flat-to-low single-digit growth and stronger H2, supported by improving US biotech funding ($23 billion raised in last 12 weeks) and accelerating interest from large pharma companies pursuing China+1 supply chain diversification. PAT growth is expected to be single-digit due to rising effective tax rate (~23% vs ~21.5% underlying in FY24). The Stelis biologics facility remains on track for H2 2024 commissioning, which will triple biomanufacturing capacity. Key risk: extended capacity ramp-up timeline and competitive pressure from large-scale global CDMO players.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects improved demand situation with high single-digit to low double-digit growth on constant currency basis, building from 6% constant currency growth in FY24. First half expected to be relatively flat to low single-digit, with stronger second half driven by biotech funding recovery and pharma diversification trends.
- Operating EBITDA margin expected to be roughly stable year-over-year, reflecting continued investments in capacity and capabilities while benefiting from operational efficiencies.
- Profit after tax growth anticipated to be single-digit due to headwind from increased effective tax rate rising to approximately 23% from underlying 21.5% in FY24, partially offset by operational improvements.
- Planned capital expenditure of $60 million with approximately 50% for research services (Hyderabad land development, automation, Bangalore facility), 40% for CDMO business including Stelis biologics plant qualification, and 15% for digitization and ESG initiatives.
Risks flagged
- Q4 performance was significantly impacted by reduced US biotech funding, causing clients to defer or cancel projects. While $23 billion of new funding flowed in recently, the translation to actual demand remains uncertain with 12-18 week lag.
- The acquired biologics facility will spend most of FY25 in upgrade and qualification phase with minimal revenue contribution expected. This delays payback on the acquisition investment.
- Analyst raised concerns about slower-than-expected traction in the Bangalore API facility despite multiple years of waiting. Management deflected with generic CDMO strategy commentary without specific timeline commitments.
- Large competitors like Samsung (2.8 lakh liter capacity) and Lonza are expanding aggressively in biologics manufacturing. Syngene's strategy focuses on small-to-medium biotech and clinical-scale manufacturing, but this limits addressable market.
Key quotes
- Q4 revenue from operations declined by 8% over the corresponding quarter last year. The quarter really marks the end to what was a tough year for many in the pharma-based research sector.
- I'm pretty encouraged by some of the positive signals in the market. In the last 12 weeks, I think we've seen a marked improvement in that funding environment. $23 billion of new funding went into the US biotech sector in the last 12 weeks.
- We expect the first half to be relatively flat to low single-digit growth year-on-year as we build the business pipeline. We expect a stronger second half and a better exit to the year.
Research modules